Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A side effect occurring in a majority of patients taking erlotinib (Tarceva®) consists of a
skin rash. Sometimes, symptoms associated with the rash necessitate erlotinib dose reduction
or discontinuation. Some physicians have successfully treated the erlotinib-induced rash with
doxycycline. At the same time, it has been observed that in patients who develop the
erlotinib rash, the cancers respond better to erlotinib treatment. This research study is
designed to determine how well doxycycline treats the erlotinib rash and whether doxycycline
affects the blood levels of erlotinib.